Athena Athena

X

Find Radio Compass News for Ravulizumab

PharmaCompass
API SUPPLIERS
API Suppliers

API Suppliers

0

US DMFs Filed

US DMFs Filed

0

CEP/COS Certifications

CEP/COS Certifications

0

JDMFs Filed

JDMFs Filed

0

Other Certificates

Other Certificates

0

Other Suppliers

Other Suppliers

0

API REF. PRICE (USD / KG)

0

INTERMEDIATES

0

DOSSIERS // FDF
USA (Orange Book)

USA (Orange Book)

Europe

Europe

0

Canada

Canada

Australia

Australia

South Africa

South Africa

0

Uploaded Dossiers

Uploaded Dossiers

0

GLOBAL SALES (USD Million)

U.S. Medicaid

Annual Reports

0

EXCIPIENTS

0

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

0

USFDA Exclusivities

0

DIGITAL CONTENT

Blog #PharmaFlow

News

REF STANDARD

EDQM

0

USP

0

JP

0

Other Listed Suppliers

0

SERVICES

0

https://www.fiercepharma.com/pharma/astrazenecas-rare-disease-unit-overcomes-fda-snub-expand-ultomiris-nmosd

FIERCE PHARMA
26 Mar 2024

https://www.businesswire.com/news/home/20240325711806/en

BUSINESSWIRE
25 Mar 2024

https://www.astrazeneca.com/media-centre/press-releases/2024/voydeya-recommended-for-eu-approval.html

PRESS RELEASE
26 Feb 2024

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761108

FDA
08 Feb 2024

https://www.businesswire.com/news/home/20231210304747/en

BUSINESSWIRE
10 Dec 2023

https://www.biospace.com/article/fda-rejects-astrazeneca-s-ultomiris-label-expansion-in-nmosd/#:~:text=The%20FDA%20has%20denied%20AstraZeneca,disorder%2C%20the%20company%20announced%20Wednesday.

BIOSPACE
07 Sep 2023

https://www.onclive.com/view/the-evolving-treatment-landscape-in-paroxysmal-nocturnal-hemoglobinuria

ONCLIVE
30 Jun 2023

https://www.pharmatimes.com/news/astrazenecas_ultomiris_approved_in_japan_for_prevention_of_relapses_in_patients_with_nmosd_1492208

Betsy Goodfellow PHARMATIMES
30 May 2023

http://pharmabiz.com/NewsDetails.aspx?aid=159391&sid=2

PHARMABIZ
27 May 2023

https://www.pharmaceutical-technology.com/news/astrazenecas-ultomiris-japanese-approval-nmosd/

PHARMACEUTICAL TECHNOLOGY
26 May 2023

http://www.pharmabiz.com/NewsDetails.aspx?aid=158150&sid=2

PHARMABIZ
17 May 2023

http://pharmabiz.com/NewsDetails.aspx?aid=158048&sid=2

PHARMABIZ
11 May 2023

https://www.astrazeneca.com/media-centre/press-releases/2023/ultomiris-approved-in-the-eu-for-adults-with-neuromyelitis-optica-spectrum-disorder-nmosd.html

PRESS RELEASE
10 May 2023

https://www.astrazeneca.com/media-centre/press-releases/2023/ultomiris-recommended-for-nmosd-eu-approval.html

PRESS RELEASE
04 Apr 2023

http://pharmabiz.com/NewsDetails.aspx?aid=154083&sid=2

PHARMABIZ
27 Oct 2022

https://www.businesswire.com/news/home/20221027005147/en

BUSINESSWIRE
27 Oct 2022

https://www.businesswire.com/news/home/20221011006006/en

BUSINESSWIRE
12 Oct 2022

https://www.pharmaceutical-technology.com/news/ec-alexion-ultomiris-myasthenia-gravis/

PHARMACEUTICAL-TECHNOLOGY
27 Sep 2022

https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2022/ultomiris-approved-in-eu-for-gmg.html

PRESS RELEASE
23 Sep 2022

https://www.businesswire.com/news/home/20220916005089/en

BUSINESSWIRE
16 Sep 2022

https://www.biospace.com/article/releases/danicopan-alxn2040-add-on-to-ultomiris-ravulizumab-cwvz-or-soliris-eculizumab-met-primary-endpoint-in-alpha-phase-iii-trial-for-patients-with-paroxysmal-nocturnal-hemoglobinuria/?s=69

BIOSPACE
16 Sep 2022

https://www.biospace.com/article/astrazeneca-makes-waves-in-japan-with-approvals-for-tagrisso-ultomiris-and-lynparza/

Vanessa Doctor BIOSPACE
26 Aug 2022

https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2022/ultomiris-approved-in-japan-for-the-treatment-of-adults-with-generalised-myasthenia-gravis.html

PRESS RELEASE
25 Aug 2022

https://www.prnewswire.com/news-releases/argenxs-vyvgart-and-alexions-ultomiris-go-toe-to-toe-in-generalized-myasthenia-gravis-according-to-spherix-global-insights-301611961.html

PRNEWSWIRE
24 Aug 2022

https://endpts.com/on-a-roll-astrazeneca-flags-looming-approvals-for-three-big-drug-franchises/

John Carroll ENDPTS
26 Jul 2022

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761108

FDA
22 Jul 2022

https://www.businesswire.com/news/home/20220428005462/en

BUSINESSWIRE
28 Apr 2022

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761108

FDA
27 Apr 2022

https://www.businesswire.com/news/home/20220406005286/en

BUSINESSWIRE
06 Apr 2022

https://www.fiercepharma.com/pharma/roche-chugai-astrazeneca-alexion-settle-ultomiris-patent-lawsuit

Angus Liu FIERCEPHARMA
19 Feb 2022

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761108

FDA
07 Jan 2022

https://www.astrazeneca.com/media-centre/press-releases/2021/ultomiris-accepted-for-fda-priority-review-for-gmg.html

ASTRAZENECA
21 Dec 2021

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761108

FDA
22 Nov 2021

https://www.businesswire.com/news/home/20210715006015/en

BUSINESS WIRE
15 Jul 2021

https://www.businesswire.com/news/home/20210607005638/en

BUSINESSWIRE
07 Jun 2021

https://www.businesswire.com/news/home/20210607005638/en/%C2%A0Alexion-Announces-FDA-Approval-of-ULTOMIRIS%C2%AE-ravulizumab-cwvz-for-Children-and-Adolescents-with-Paroxysmal-Nocturnal-Hemoglobinuria-PNH#:~:text=ULTOMIRIS%2C%20a%20long%2Dacting%20C5,children%20and%20adolescents%20with%20PNH.&text=It\'s%20exciting%20to%20finally%20have,who%20are%20diagnosed%20as%20children.%E2%80%9D

BUSINESSWIRE
07 Jun 2021

https://www.globenewswire.com/news-release/2021/05/12/2228361/0/en/Apellis-to-Present-Long-Term-Pegcetacoplan-Data-in-PNH-at-the-European-Hematology-Association-Virtual-Congress.html

GLOBENEWSWIRE
12 May 2021

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761108

FDA
22 Apr 2021

https://www.fiercepharma.com/marketing/alexion-wins-nice-backing-for-ultomiris-pnh-as-atypical-hus-decision-awaits

Angus Liu FIERCE PHARMA
16 Apr 2021

http://www.pmlive.com/pharma_news/alexion_and_nice_agree_confidential_discount_for_ultomiris_use_on_the_nhs_1367231

Lucy Parsons PMLIVE
16 Apr 2021

https://pharmaphorum.com/news/nice-recommends-alexions-long-acting-ultomiris-for-pnh/#:~:text=NICE%20has%20recommended%20Alexion's%20long,schedule%20after%20a%20loading%20phase.

Richard Staines PHARMAPHORUM
16 Apr 2021

https://www.thepharmaletter.com/article/nice-backs-ultomiris-for-adult-patients-with-pnh?__cf_chl_jschl_tk__=05ae265e2d7a30fa74c7378e0e3af7d7c487fac8-1618567066-0-Ad1i1wglZy82v3-Wl8s_PG0vNpjxq7oB7nseaMD9p-J-C_oviWJgqCsi2mXkm3hoF6rtpX6NcUE4tNfT1vhsgxO2_rvEXM7nwYYkHDdGPjYl7agdXL102AeTooXdrYxbJjyZiIVxAJ2nhHp5_WqrJKIwQyVACv7EjBUdHMsmksYckO89ifFBDndScttzTEP58xLTACa3wQuyDRmorodt0ArT5Fmv_eTNYUZTgayyVRlVMEnIK7iLCL4isa-oNl9mqeVzfKKonYt4DMj2MWdg7LdqqAQD3CmvZES0ZLB8mu7wr-C0mLn2q6E-6xJxXG7EQxutFK07akwjeLKUBxMg8ehozO_45N2Aw0SC10qys-tyxIbMyH6gFnqpZumJwKX2A_EXnellUtjOYP45GmIwUWsieErV5nuRg_RD4pLrSLilyOMvECfQzvUwx4HW42CpSHzdHx4rj_5BrO5RwQb9cT3le47WU_4TULwJdrrbAhTDE3fVAM4gngcpN1xqE8FOMw

NEUROEUROPE
15 Apr 2021

https://www.bloomberg.com/press-releases/2021-01-13/alexion-provides-update-on-phase-3-study-of-ultomiris-ravulizumab-cwvz-in-hospitalized-patients-with-severe-covid-19

BLOOMBERG
14 Jan 2021

https://globalarbitrationreview.com/korean-biotech-company-liable-in-gene-therapy-dispute

Cosmo Sanderson GLOBALARBITRATIONREVIEW
14 Jan 2021

https://www.businesswire.com/news/home/20210113005889/en

BUSINESSWIRE
13 Jan 2021

https://www.fiercepharma.com/drug-delivery/alexion-snares-approval-for-new-ultomiris-formulation-teeing-up-speedy-infusions-and

Fraiser Kansteiner FIERCE PHARMA
16 Oct 2020

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761108

FDA
14 Oct 2020

https://ir.alexion.com/news-releases/news-release-details/alexion-receives-fda-approval-new-advanced-formulation

PRESS RELEASE
12 Oct 2020

https://seekingalpha.com/news/3617307-alexions-ultomiris-okd-in-japan

Vandana Singh SEEKING ALPHA
25 Sep 2020

https://www.businesswire.com/news/home/20200925005244/en

BUSINESSWIRE
25 Sep 2020
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY